Resources

Formulation Development Packages for LNP & PNP (Screening, Analytics & Stability)

Back to resources
Check other formulation packages

Discover Curapath’s structured approach to LNP and PNP formulation development. Our tiered packages combine screening, analytical rigor and stability strategies tailored for early discovery through preclinical readiness.

Form

Fill Out The Form To Begin Your Download

Curapath has launched a tiered suite of Formulation Development Packages to accelerate the design and optimization of Lipid Nanoparticle (LNP) and Polymer Nanoparticle (PNP) systems for nucleic acid and peptide delivery. These packages, Essential, Advanced, and Expert, are built to offer increasing levels of complexity, analytical depth, and formulation flexibility.
Formulation Development Services MA (1)

Each package includes access to proprietary and alternative lipids and polymers, enabling the development of high-quality, non-viral drug delivery systems tailored to a wide variety of payloads. From rapid formulation screening and foundational analytics to reporter gene assays and full characterization studies, Curapath’s packages are designed to meet the evolving needs of preclinical and clinical-stage programs.

Learn how these customizable, cost-effective solutions can support your formulation goals and streamline early-stage development. Download the complete overview of our formulation packages here.

What you’ll get in the download

A clear and structured overview of Curapath’s formulation development services, designed to help you quickly assess the scope, depth and flexibility of our LNP and PNP packages.

In this document, you will find:

  • The analytical depth available per package, covering key parameters such as particle size, PDI, encapsulation efficiency, nucleic acid content and identity testing
  • Stability study design options, including number of samples, timepoints and customized storage conditions
  • Available options to support FTO-driven formulation strategies, industry standards and access to innovative excipients and shielding solutions, including PEG alternatives
  • Optional in vitro evaluation capabilities to support data-driven candidate selection and preclinical readiness

All packages are designed with scalability, CMC strategy and GMP-readiness in mind, enabling a smooth transition from early formulation development toward advanced preclinical programs.

Formulation Development Packages

Frequently asked Questions

Curapath is a European Contract Development and Manufacturing Organization (CDMO) specialized in lipid- and polymer-based delivery systems. We support biotech and pharmaceutical companies from early development through GMP-ready manufacturing.


Our core expertise includes polymer and lipid excipients, lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), polymer–drug conjugates, and coating polymers.

In this page you will find the packages for both LNPs and PNPs. There are options availble for PLGA-PLA nanoparticles 

YYes. Within our formulation development packages, we offer options designed to support freedom-to-operate (FTO) strategies, as well as industry-standard formulations.
In addition, we provide access to a library of innovative components, including alternative shielding polymers, ionizable lipids and functional polymers, to support differentiated formulation design

 

Yes. Curapath develops and manufactures PEG alternatives for drug delivery applications, including advanced polymers designed to address limitations associated with PEGylation, such as immunogenicity and long-term safety concerns.

Absolutely. The document is designed for biotech and pharma teams working at different stages, from early formulation feasibility to advanced preclinical programs requiring deeper analytical and in vitro evaluation.

Yes. Curapath has strong expertise in the development and manufacturing of targeted lipid nanoparticles (tLNPs) designed to enable extrahepatic delivery.
We support targeted LNP programs through a fully integrated workflow, covering formulation development, surface functionalization, analytical characterization and GMP-ready manufacturing.

Our LNPs can be targetted to your desired target for intance we can create aesily T-cell targetted LNPs

To know more about our conjuation ligand visit our partners website: Cristal therapeutics

 

Depending on the selected package, analytical characterization may include particle size and PDI, encapsulation efficiency, nucleic acid content, identity testing, and stability assessment under customized conditions.

 

Absolutely. All formulation development packages can be customized based on your payload (nucleic acids, peptides or small molecules), target product profile, delivery route, and development stage.

Contact
Lipid-Nanopeptide_0
Support for Your Therapeutic Program

Contact a Chemist Today

Contact Us, and we can discuss your specific therapeutic program and how Curapath can help build the right solution to advance your unique drug.